SBRT reduces acute toxicities in Asians with early-stage prostate cancer
Stereotactic body radiotherapy (SBRT) is associated with significantly lower rates of acute gastrointestinal (GI) and genitourinary (GU) toxicities compared with conventional fractionated intensity-modulated radiotherapy (CF-IMRT) in Asian patients with early-stage localized prostate cancer.
These results, from a randomized phase II study (n=64) reported at the European Society for Medical Oncology (ESMO) Asia 2018 Congress, suggest that SBRT (5 fractions) is a safe treatment option for Asians with low- or intermediate-risk localized prostate cancer when compared with CF-IMRT (38 fractions). [Poon DMC, et al, ESMO Asia 2018, abstract 218P]“Patients in the SBRT group had significantly lower rates of grade ≥1 acute GI toxicities and grade ≥2 acute GU toxicities than those in the CF-IMRT group [35 percent vs 87 percent (p<0.0001) and 3 percent vs 24 percent (p=0.0426), respectively],” reported Dr Darren Poon of the Chinese University of Hong Kong. “No grade ≥3 acute toxicities were reported in either group.”